Goodyear Tire & Rubber Co vs Mesoblast Limited — how do they compare? Goodyear Tire & Rubber Co trades at $7.09 (market cap $1.94B), while Mesoblast Limited trades at $19.12 (market cap $2.31B). The key difference: Mesoblast Limited is the larger of the two by market cap, and Mesoblast Limited is trading nearer its 52-week high, Goodyear Tire & Rubber Co nearer its low. Which is the better fit depends on your goals.
| GT | MESO | |
|---|---|---|
Market Cap | $1.94B | $2.31B |
Sector | Consumer Cyclical | Technology |
52-Week High | $11.54 | $20.96 |
52-Week Low | $5.58 | $11.35 |
Enterprise Value | $9.25B | $2.32B |
Signals from Pluang's Aura AI — not financial advice
Goodyear Tire & Rubber (GT) trades at $6.66, up 0.3% with neutral technical signals. The stock shows mixed fundamentals with attractive valuation ratios (P/E 4.69, P/B 0.64) but negative profitability (ROE -52.56%, net margin -11.64%). Recent Q1 2026 earnings beat estimates despite a loss, while the company transitions to S&P SmallCap 600. Cash flow improved in 2025 with $46M net inflow, though revenue declined to $18.28B.
Outlook remains challenging with declining revenue and negative margins, though deep value metrics and analyst consensus target of $8.75 suggest upside potential. Key risks include persistent operational headwinds, weak tire demand, and high debt levels. The Goodyear Forward program and lunar tire contract provide strategic catalysts amid competitive pressures.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →